



The Manager
Company Announcements Office
ASX Limited

LBT KEY EUROPEAN PATENT GRANTED

2 February 2010, Adelaide: LBT Innovations Limited (formerly LabTech Systems) (ASX: LBT) the Australian clinical and diagnostic technology developer, has been advised that the European Patent Office has granted its patent for the agar plate streaking technology which is at the core of the company's MicroStreak® system.

The European patent secures LBT's intellectual property in 27 countries and adds to the previously full grant of the patent in Australia.

CEO and Managing Director of LBT Innovations Lusia Guthrie said, "This is the most important patent protection to date as it covers key technology in one of the company's most important market regions."

"This European patent grant is an important step forward for LBT as the technology gains traction in laboratories in Europe and around the world," she said.

The European patent covers the methods and unique design of the agar plate streaker, which was licensed to French diagnostics company bioMérieux in 2007.

The Australian-developed technology was launched late last year across global pathology markets. It is marketed by bioMérieux as PREVI™ Isola.

A number of these automated systems have now been installed in laboratories in the United States, Europe and China. European countries already using this revolutionary technology include France, Germany, the Netherlands, Sweden, Switzerland, Belgium and the UK.

It was on 21 January 2010 that the European Patent Office granted a European patent for the invention titled "Microbial Streaking Device". European patent 1720971 was granted to Medvet Science Pty Ltd and will have effect from 17 February 2010 in those European countries where the grant is being validated. Medvet has exclusively licensed worldwide rights to the microbial streaking technology to LBT Innovations.

This technology was invented by John Glasson and Lachlan Smith who at the time of the patent filing worked at the Institute of Medical and Veterinary Science (IMVS) in Adelaide.

--ENDS--

About LBT Innovations

LBT Innovations is an Australian developer of clinical and diagnostic technology. Based in Adelaide, South Australia, the Company was formed in 2004 and listed on the Australian Securities Exchange on 31 July 2006 (ASX: LBT). The focus of the company has been the commercialisation of its first product, known as MicroStreak®.

In 2007, LBT Innovations signed an agreement with French diagnostics giant bioMérieux to commercialise and market this invention, which is now known as PREVI™ Isola. This instrumentation product comprises a central part of bioMérieux's FMLA™ (Full Microbiology Lab Automation™) strategy.

Going forward, LBT Innovations intends to continue its track record of innovation in microbiology, while also fully exploiting its existing commercial relationships and intellectual property portfolio.

For more information, see www.lbtinnovations.com

CONTACTS

LBT Innovations	Media Relations
Lusia Guthrie CEO & MD Tel: +61 (0)8 8227 1555 E: info@lbtinnovations.com	Emma Power / Rudi Michelson Monsoon Communications Tel: +61 (0)3 9620 3333 E: emmap@monsoon.com.au